Study Group

Hearing loss company Acousia announces first patient enrolled in its Phase 2 PROHEAR-Study

Retrieved on: 
Thursday, February 15, 2024
Culture, Survivor, CMO, Study Group, Ototoxicity, Risk, Gesellschaft mit beschränkter Haftung, Ear, Cisplatin, Therapy, Fatigue, Life expectancy, The German, Patient, Social, Testicular cancer, Cancer, Pharmaceutical industry

TÜBINGEN, Germany, Feb. 15, 2024 /PRNewswire/ -- Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, just announced the randomization of the first patient for the PROHEAR-Study.

Key Points: 
  • TÜBINGEN, Germany, Feb. 15, 2024 /PRNewswire/ -- Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, just announced the randomization of the first patient for the PROHEAR-Study.
  • Germ-cell testicular cancer is the most common cancer among young men, with incidence rates continuously increasing.
  • In preclinical models, ACOU085 has demonstrated its significant potential to reduce cisplatin-induced hearing loss and preserve outer hair cells from ototoxicity.
  • "The enrollment of the first patient into our ACOU085 Clinical Phase 2 program marks a further major milestone in our efforts to finally make acute and subacute forms of hearing loss treatable" said Dr. Tim Bölke, CEO and CMO of Acousia Therapeutics.

Hearing loss company Acousia announces first patient enrolled in its Phase 2 PROHEAR-Study

Retrieved on: 
Thursday, February 15, 2024
Culture, Survivor, CMO, Study Group, Ototoxicity, Risk, Gesellschaft mit beschränkter Haftung, Ear, Cisplatin, Therapy, Fatigue, Life expectancy, The German, Patient, Social, Testicular cancer, Cancer, Pharmaceutical industry

TÜBINGEN, Germany, Feb. 15, 2024 /PRNewswire/ -- Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, just announced the randomization of the first patient for the PROHEAR-Study.

Key Points: 
  • TÜBINGEN, Germany, Feb. 15, 2024 /PRNewswire/ -- Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, just announced the randomization of the first patient for the PROHEAR-Study.
  • Germ-cell testicular cancer is the most common cancer among young men, with incidence rates continuously increasing.
  • In preclinical models, ACOU085 has demonstrated its significant potential to reduce cisplatin-induced hearing loss and preserve outer hair cells from ototoxicity.
  • "The enrollment of the first patient into our ACOU085 Clinical Phase 2 program marks a further major milestone in our efforts to finally make acute and subacute forms of hearing loss treatable" said Dr. Tim Bölke, CEO and CMO of Acousia Therapeutics.

Domain Therapeutics Awarded Hospital-University Research in Health (RHU) SPRINT Consortium Grant to Progress Its Proprietary CCR8 Antibody Candidate to the Clinic

Retrieved on: 
Thursday, January 25, 2024
Technology, Biotechnology, Health, Biometrics, Other Health, Pharmaceutical, Artificial Intelligence, Oncology, Other Science, Research, Hospitals, Health Technology, Science, Clinical Trials, Patient, Therapy, G protein-coupled receptor, AP-HP, Multimedia, Fatigue, Intelligence, Medicen, Government, Cancer, Cutaneous T-cell lymphoma, Drug discovery, Quality of life, SPRINT, Survival rate, Regulatory T cell, National Cancer Institute, Disease, Study Group, Sarcoma, Hospital, GPCR, Pain, Gq alpha subunit, ANR, TME, RHU, Physician, Pharmaceutical industry

Domain Therapeutics (“Domain” or “the Company”), a clinical-stage global biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), today announces it has been awarded a grant as part of the Hospital-University Research in Health (RHU) SPRINT consortium.

Key Points: 
  • Domain Therapeutics (“Domain” or “the Company”), a clinical-stage global biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), today announces it has been awarded a grant as part of the Hospital-University Research in Health (RHU) SPRINT consortium.
  • View the full release here: https://www.businesswire.com/news/home/20240125583037/en/
    The SPRINT project aims to revolutionize the management of patients with CTCL and deliver a new cure paradigm as a standard-of-care.
  • The grant that we have been awarded by the RHU SPRINT consortium will support the progress of DT-7012, an anti-CCR8 monoclonal antibody which has incredible potential as a best-in-class therapeutic, into the clinic.
  • Domain was already awarded a first RHU grant, RHU CONDOR for Sarcoma, in the previous campaign, leveraging another proprietary asset.

Alzheimer's Association Mourns Death of Former Supreme Court Justice Sandra Day O'Connor

Retrieved on: 
Friday, December 1, 2023
Alzheimer's disease, Life, Justice, Disease, Supreme court, Caregiver, Dementia, Doctor of Public Health, Diagnosis, Alzheimer's Association, Death, Study Group, Family, Human, Residential care

CHICAGO, Dec. 1, 2023 /PRNewswire/ -- The Alzheimer's Association is saddened by the death of former Supreme Court Justice Sandra Day O'Connor.

Key Points: 
  • CHICAGO, Dec. 1, 2023 /PRNewswire/ -- The Alzheimer's Association is saddened by the death of former Supreme Court Justice Sandra Day O'Connor.
  • At the time of her diagnosis, Justice O'Connor was not new to Alzheimer's.
  • In 2005, as Mr. O'Connor was in decline from the disease, Justice O'Connor stepped down from the Supreme Court to spend more time with him.
  • "The Alzheimer's Association mourns the loss of former Supreme Court Justice Sandra Day O'Connor.

Emily Williams Knight, Ed.D. joins Operation Homefront's National Board of Directors

Retrieved on: 
Wednesday, October 11, 2023
India Reloaded: Inside India's Resurgent Consumer Market, School, COVID-19, TRA, American City Business Journals, Boston University, Government, OUR, Restaurant, Study Group, Les Roches International School of Hotel Management, Newbury College, Mark Baring (hospital administrator), Southern New Hampshire University, University, Laureate, Education, Knight, Operation Homefront, Walden University, Higher education leadership, The Foundation for Young Australians, International business, Kendall College, SAN, API, Glion, Humanities, Face, Nation's Restaurant News, Troy University, Management, Nursing, Science

SAN ANTONIO, Oct. 11, 2023 /PRNewswire-PRWeb/ -- Operation Homefront, a leading national nonprofit dedicated to serving America's military families, has elected Dr. Emily Williams Knight, CEO of the Texas Restaurant Association and Education Foundation, to its national board of directors.

Key Points: 
  • SAN ANTONIO, Oct. 11, 2023 /PRNewswire-PRWeb/ -- Operation Homefront, a leading national nonprofit dedicated to serving America's military families, has elected Dr. Emily Williams Knight, CEO of the Texas Restaurant Association and Education Foundation, to its national board of directors.
  • "I am thrilled Emily will be joining our very talented board of directors," said Brig Gen (ret) John I. Pray, Jr., President and CEO of Operation Homefront.
  • "On behalf of our entire board, I want to welcome Emily to Operation Homefront," said Uli Correa, chair of Operation Homefront's board of directors.
  • Knight also serves on the Texas Travel and Tourism Board, the University of North Texas School of Hospitality Advisory Board, and the Texas Business Roundtable.

ISUZU ELF Adopts Hitachi Astemo Sensing System

Retrieved on: 
Friday, July 14, 2023
Dam safety system, Ministry of Land, Infrastructure, Transport and Tourism, Accident, Drivetrain, Transport, ELF, Ministry, Report, Isuzu Giga, Study Group, Knowledge, Growth, Tourism, Environment, Pedestrian, Safety, Road, Isuzu

TOKYO, July 14, 2023 - (JCN Newswire) - Hitachi Astemo Ltd. announced that Isuzu Motors Limited adopted its sensing system in its new ELF model.

Key Points: 
  • TOKYO, July 14, 2023 - (JCN Newswire) - Hitachi Astemo Ltd. announced that Isuzu Motors Limited adopted its sensing system in its new ELF model.
  • Using a wide-angle stereo camera, the sensing system enables collision damage mitigation braking at intersections and on single-track roads.
  • Based on Isuzu's extensive knowledge of commercial vehicles, Hitachi Astemo developed a sensing system for Isuzu trucks that takes into account truck-specific use cases, along with the specification settings needed for achieving collision mitigation during right and left turns at intersections.
  • The sensing system employed in the new ELF model utilizes a 120-degree wide-angle stereo camera, enabling an expanded detection range.

Exscientia Initiates Prospective Observational Study in Ovarian Cancer

Retrieved on: 
Tuesday, July 18, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Health Technology, Clinical Trials, Observational study, Cancer, EVP, Personalized medicine, Evangelische Arbeitsgemeinschaft für Kirchliche Zeitgeschichte, PFS, Patient, Study Group, Ovarian cancer, AGO, Medical imaging

Exscientia plc (Nasdaq: EXAI) today announced the initiation of EXCYTE-1, a prospective observational study in ovarian cancer to investigate the relationship between ex vivo drug response (EVDR) in primary tumour-derived samples using the company’s precision medicine platform and actual patient clinical response.

Key Points: 
  • Exscientia plc (Nasdaq: EXAI) today announced the initiation of EXCYTE-1, a prospective observational study in ovarian cancer to investigate the relationship between ex vivo drug response (EVDR) in primary tumour-derived samples using the company’s precision medicine platform and actual patient clinical response.
  • This first of its kind observational study in solid tumours will run at multiple medical research centres in Europe with a focus on ovarian cancers.
  • Ovarian cancer represents a high unmet need for predicting patient response to diverse therapy options.
  • The study will be conducted in collaboration with the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Study Group, one of the leading non-profit clinical research networks in gynaeco-oncology worldwide.

Toyota Launches the C+walk S in Japan, a New Form of Walking-Assistance Mobility

Retrieved on: 
Monday, March 20, 2023
Heart, Communication, Travel, Classification, Transport, Ageing, Traffic, Road Traffic Act 1934, Research, Sale, Ministry, Local government, Walking, Study Group, Rest, Pedestrian, Ministry of Land, Infrastructure, Transport and Tourism, Automotive industry, Road

Toyota City, Japan, Mar 20, 2023 - (JCN Newswire) - Toyota Motor Corporation (Toyota) announced today that it will release the C+walk S, a pedestrian-mobility-assistance model that is the second in the new C+walk mobility series.

Key Points: 
  • Toyota City, Japan, Mar 20, 2023 - (JCN Newswire) - Toyota Motor Corporation (Toyota) announced today that it will release the C+walk S, a pedestrian-mobility-assistance model that is the second in the new C+walk mobility series.
  • The C+walk S will go on sale at Toyota automobile dealers and be offered at rental and leasing stores from March 20, 2023(1).
  • Toyota has continued to provide customers with a variety of options to bring "Mobility for All."
  • Toyota will explore the potential of using these mobility vehicles to complement regional transportation in order to achieve a better mobility society.

Agendia Announces First Patient Enrolled in PROOFS Registry Trial to Determine Optimal Treatment and Ability to Forgo Chemotherapy for Premenopausal Women with Early HR+ Breast Cancer

Retrieved on: 
Thursday, March 16, 2023
Research, Women, Genetics, Clinical Trials, Biotechnology, Consumer, Health, Science, Oncology, Other Science, Cancer, Quality of life, Breast cancer, PD, Gene expression profiling, MD, WSG, Survival, Risk, Partnership, Pathology, Fertility, Patient, Toxicity, Biology, Woman, OFS, Gene expression, Study Group, University of Cologne, University, Toxic leukoencephalopathy, Birth control, MammaPrint, EV

Agendia, Inc. , a leader in gene expression profiling for early-stage breast cancer, today announced the first patient has been enrolled in the PROOFS Registry trial.

Key Points: 
  • Agendia, Inc. , a leader in gene expression profiling for early-stage breast cancer, today announced the first patient has been enrolled in the PROOFS Registry trial.
  • Breast cancer uses estrogen to grow, and chemotherapy suppresses the ovaries’ production of estrogen to cut off the cancer’s fuel source.
  • Every young woman with early-stage breast cancer deserves the right to make truly informed treatment decisions tailored to her unique biology.
  • These insights could allow some young women with breast cancer to forgo chemotherapy and avoid unnecessary toxicity,” said William Audeh, MD, Chief Medical Officer at Agendia.

Researchers from Rowan University and Durin Technologies announce highly accurate blood test for Alzheimer's Disease

Retrieved on: 
Wednesday, March 8, 2023
Journal, Research, Ageing, Biomarker, Disease, Rowan-Virtua School of Osteopathic Medicine, Patient, Parkinson, Autoantibody, Pathology, Study Group, Osteopathic medicine in the United States, AD, American Journal of Alzheimer's Disease & Other Dementias, New Jersey Institute of Technology, Medical imaging, Alzheimer's disease, Geriatrics

STRATFORD, N.J., March 8, 2023 /PRNewswire/ -- A team of researchers from Rowan-Virtua School of Osteopathic Medicine (Rowan-Virtua SOM) and Durin Technologies, Inc., have announced the results of a newly-designed blood test that can detect the presence of Alzheimer's disease-related pathology up to 10 years before symptoms arise with a nearly 97 percent accuracy rate. Their findings appear online ahead of press in the Journal of Alzheimer's Disease.

Key Points: 
  • Their findings appear online ahead of press in the Journal of Alzheimer's Disease .
  • The study involved 328 blood samples with the goal of determining if a test that monitors a small number of a patient's autoantibodies can detect Alzheimer's disease (AD)-related pathology at pre-symptomatic, prodromal (i.e., mild cognitive impairment), and mild-moderate stages of the disease.
  • "To our knowledge, this is the first blood test to accurately detect Alzheimer's-related pathology several years before either clinical symptoms or more expensive and invasive tests can identify the disease."
  • For a number of reasons, the test has significant potential to impact effective treatments for Alzheimer's disease.